Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nektar Therapeutics

www.nektar.com

Latest From Nektar Therapeutics

After The Peak Of 2018’s US FDA Approval Record, 2019 Looks Like A Valley

FDA’s second half 2019 user fee calendar features almost 30 novel agents, but another record-breaking tally is out of reach.

Approvals Drug Approval Standards

Keeping Track: A Busy Week For Regenerative Medicine, A Surprise Priority Review For Vascepa, And Tazemetostat Aims For Accelerated Approval

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Regulation

OptumRx WatchList Includes Rare Disease Drugs, Potential Price Disruptors

Pharmacy benefit manager’s new pipeline report offers insight into upcoming drugs of concern to payers.

Commercial Pharmacy Benefit Management

Finance Watch: Three New Biopharma IPOs In The US With Eight More Entering The Queue

Public Company Edition: IPO performance has been mixed in 2019, but May has been the busiest month this year. Also, Insmed leads recent follow-on offerings and Dynavax restructures.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Inhale Therapeutic Systems Inc.
  • Nektar Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Nektar Therapeutics
  • Senior Management
  • Howard W Robin, Pres. & CEO
    Gil M Labrucherie, SVP, CFO
    Stephen K Doberstein, PhD, SVP, R&D and Chief R&D Officer
  • Contact Info
  • Nektar Therapeutics
    Phone: (415) 482-5300
    455 Mission Bay Blvd. S.
    San Francisco, CA 94158
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register